Cognition Therapeutics (NASDAQ: CGTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.320 | -0.250 | 0.0700 | ||||
REV | 0 |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.170 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cognition Therapeutics (NASDAQ: CGTX) through any online brokerage.
Other companies in Cognition Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), Cumberland (NASDAQ:CPIX), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP) and Ocuphire Pharma (NASDAQ:OCUP).
The latest price target for Cognition Therapeutics (NASDAQ: CGTX) was reported by Ladenburg Thalmann on Friday, April 22, 2022. The analyst firm set a price target for 10.00 expecting CGTX to rise to within 12 months (a possible 390.17% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Cognition Therapeutics (NASDAQ: CGTX) is $2.0401 last updated Today at August 15, 2022, 3:09 PM UTC.
There are no upcoming dividends for Cognition Therapeutics.
Cognition Therapeutics’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Cognition Therapeutics.
Cognition Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.